Gilead Sciences, Inc. Reports Third Quarter 2026 Financial Results and Updates Full Year Guidance

Gilead Sciences, Inc. reported its financial results for the third quarter ended September 30, 2026. Total product sales...

By Dhallo News · October 30, 2026 at 7:32 AM IST

Gilead Sciences, Inc. reported its financial results for the third quarter ended September 30, 2026. Total product sales increased 13% to $8.3 billion compared to the same period in 2025, driven by higher sales of HIV products, Trodelvy, and Livdelzi, and partially offset by lowe

SOURCE: Nasdaq

ORIGINAL REPORT: Click here

DHALLO EDITORIAL STATUS: Aggregated & reviewed

Have feedback on this article?Report error or suggestion

Gilead Sciences, Inc. Reports Third Quarter 2026 Financial Results and Updates Full Year Guidance

Read More from Markets

Bruker Corporation Declares Quarterly Cash Dividend of $3.9844 Per Share on Series A Mandatory Convertible Preferred Stock

Unified Patent Court Rules Enanta Pharmaceuticals, Inc. Patent EP 4 051 265 Invalid

'Must make immediate, creative decisions': What CEO of 'never-ending' cruise that stranded 200 people said in his letter

5 minutes. The news that matters.